We are live on
!
Find out more
EMG
ETF Managers Group Portfolio holdings
AUM
$3.1B
1-Year Est. Return
17.12%
This Fund
S&P 500
This Quarter
Est. Return
+18.48%
1 Year Est. Return
-17.12%
3 Year Est. Return
+77.69%
5 Year Est. Return
+63.88%
10 Year Est. Return
–
AUM
$5.63B
AUM Growth
+$1.07B
(+23%)
Cap. Flow
+$732M
Cap. Flow
% of AUM
13%
Top 10 Holdings %
Top 10 Hldgs %
19.89%
Holding
695
New
78
Increased
409
Reduced
177
Closed
27
Top Buys
| 1 |
Cognyte Software
CGNT
|
+$51.8M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$45.4M |
| 3 |
Mativ Holdings
MATV
|
+$37.9M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$37.4M |
| 5 |
Altria Group
MO
|
+$34.6M |
Top Sells
| 1 |
Tilray
TLRY
|
+$43M |
| 2 |
APHA
Aphria Inc. Common Shares
APHA
|
+$40M |
| 3 |
VRNT
Verint Systems
VRNT
|
+$35.2M |
| 4 |
GameStop
GME
|
+$18.6M |
| 5 |
ABST
Absolute Software Corp
ABST
|
+$18M |
Sector Composition
| 1 | Technology | 42.27% |
| 2 | Healthcare | 15.02% |
| 3 | Materials | 12.66% |
| 4 | Financials | 7.72% |
| 5 | Consumer Staples | 7.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
XBiotech
XBIT
$69.8M
| $152K | ﹤0.01% |
8,963
-5,269
| -37% | -$98.4K |
|
|
CNCE
627
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $152K | ﹤0.01% |
31,327
+4,329
| +16% | +$35K |
|
|
LHDX
628
DELISTED
Lucira Health, Inc. Common Stock
LHDX
| $139K | ﹤0.01% |
+11,395
| New | +$226K |
|
|
HOOK
629
DELISTED
HOOKIPA Pharma
HOOK
| $135K | ﹤0.01% |
1,009
-240
| -19% | -$29K |
|
630
cbdMD
YCBD
$6.48M
| $134K | ﹤0.01% |
95
+2
| +2% | +$2.91K |
|
631
Tonix Pharmaceuticals
TNXP
$189M
| – | – |
0
| – | – |
|
|
FOLD
632
DELISTED
Amicus Therapeutics
FOLD
| $117K | ﹤0.01% |
12,482
-3,335
| -21% | -$51.6K |
|
|
SQZ
633
DELISTED
SQZ Biotechnologies Company
SQZ
| $110K | ﹤0.01% |
8,532
-3,128
| -27% | -$63.5K |
|
634
Cue Biopharma
CUE
$117M
| $107K | ﹤0.01% |
309
-182
| -37% | -$74.9K |
|
635
Inseego
INSG
$123M
| $103K | ﹤0.01% |
1,061
+21
| +2% | +$3.06K |
|
|
XNET
636
Xunlei
XNET
$387M
| $101K | ﹤0.01% |
15,654
-1,034
| -6% | -$6.36K |
|
637
Immunome
IMNM
$2.51B
| $100K | ﹤0.01% |
+3,250
| New | +$80.8K |
|
638
iBio
IBIO
$67.1M
| $99K | ﹤0.01% |
132
-45
| -25% | -$39.2K |
|
|
ATHX
639
DELISTED
Athersys, Inc. Common Stock
ATHX
| $99K | ﹤0.01% |
2,422
-1,424
| -37% | -$73.9K |
|
|
PRTK
640
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $96K | ﹤0.01% |
13,981
-8,218
| -37% | -$59.2K |
|
|
CDAK
641
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
| $92K | ﹤0.01% |
6,603
-2,525
| -28% | -$54.9K |
|
|
TLIS
642
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
| $90K | ﹤0.01% |
+525
| New | +$131K |
|
643
CorMedix
CRMD
$650M
| $88K | ﹤0.01% |
9,843
-5,786
| -37% | -$60.9K |
|
|
GLDD
644
DELISTED
Great Lakes Dredge & Dock
GLDD
| $86K | ﹤0.01% |
6,037
-7,167
| -54% | -$104K |
|
645
Grid Dynamics Holdings
GDYN
$485M
| $84K | ﹤0.01% |
5,294
-53
| -1% | -$762 |
|
646
Arbutus Biopharma
ABUS
$936M
| $82K | ﹤0.01% |
26,009
-15,290
| -37% | -$59K |
|
|
CODX
647
Co-Diagnostics
CODX
$9.16M
| $74K | ﹤0.01% |
289
-169
| -37% | -$67.5K |
|
648
Vontier
VNT
$4.31B
| $71K | ﹤0.01% |
2,321
+308
| +15% | +$10K |
|
|
IMV
649
DELISTED
IMV Inc. Common Shares
IMV
| $63K | ﹤0.01% |
2,052
-1,163
| -36% | -$41.3K |
|
650
Assembly Biosciences
ASMB
$512M
| $53K | ﹤0.01% |
977
-362
| -27% | -$24K |
|
Similar funds
AIA
PFM
DKP
HT
JCG
QA
BFG
IMOV
ETF Managers Group's Q1 2021 Portfolio in Review
As of Q1 2021, ETF Managers Group held 695 positions worth $5.63B, up 23% from $4.56B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
ETF Managers Group deployed $732M of net new capital in Q1 2021, opening 78 new positions and adding to 409 existing holdings. Its largest new stake was Cognyte Software: 1,743,286 shares worth $47.8M.
By sector, the portfolio is most concentrated in Technology at 42% of assets, down from 52% a quarter earlier, followed by Healthcare and Materials.
On the sell side, the largest reduction was Tilray, an estimated $43M trimmed.
- ETF Managers Group's largest Q1 2021 buy was Cognyte Software: 1,743,286 shares worth $47.8M.
- ETF Managers Group added most to GW Pharmaceuticals Plc American Depositary Shares in Q1 2021, an estimated $45.4M increase.
- ETF Managers Group's biggest Q1 2021 reduction was Tilray, cutting an estimated $43M.
- ETF Managers Group fully exited Tvardi Therapeutics in Q1 2021, selling an estimated $6.57M.
- ETF Managers Group's ten largest holdings make up 20% of its $5.63B portfolio in Q1 2021.
- ETF Managers Group opened 78 new positions and closed 27 in Q1 2021.
- ETF Managers Group's portfolio value rose 23% quarter-over-quarter to $5.63B.
Based on ETF Managers Group's 13F filing for Q1 2021, filed 17 May 2021.